Interview: Stefan Braam, CEO & Founder of Ncardia 3SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 16 July 2020 | Ncardia | No comments yet Mass production with iPSCs: how Ncardia has pushed the boundaries with high-throughput iPSC research. Ncardia is a stem cell technology company providing solutions for drug efficacy, drug safety and cell therapy. They develop custom cell models, design phenotypic assays, screen compound libraries, and enable process development and large-scale manufacturing. Read along Stefan Braam’s journey on becoming the leader in induced pluripotent stem cell work. READ MORE Related content from this organisation Application note: Validation of identified through AI Case study: Parkinson’s disease modelling for drug discovery Whitepaper: Automated cell culture and screening Interview: Stefan Braam, CEO & Founder of Ncardia Whitepaper: Neuroinflammation study Related topicsHit-to-Lead, Imaging, Screening, Stem Cells, Targets Related organisationsNcardia